Ledger. Australian venture funding, tracked

Company

Vaxxas’ core technology was initially developed at The University of Queensland

Coverage

Stories naming Vaxxas’ core technology was initially developed at The University of Queensland. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Grant $3.2m

Vaxxas Named Stage Winner of United States' BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia

Something wrong? Tell us